NeoStem's Suzhou Erye receives 2 pharma industry awards, positioned for future growth Print E-mail
By Deborah Sterescu - ProactiveInvestors.com   
Tuesday, 26 April 2011 16:51

NeoStem (AMEX:NBS) announced Tuesday that Chinese generic pharma company Suzhou Erye, in which it owns a 51% majority stake, has won two awards at the 2011 Chempharm Brand Summit, having been recognized for achievement in the industry.

During the Summit held in Chengdu City, China, Suzhou received the Top 10 Anti-Infection Drug Award and the Top 100 Brand Names Award.

The positive news comes as Suzhou Erye is transitioning to its new 53,000 square metre manufacturing facility this year, which is expected to double capacity. Two additional production line approvals at the new plant are anticipated by year end.

Suzhou Erye also has five other products in its pipeline as NeoStem and the Chinese company look to in-license or acquire new drug opportunities to further expand the business.

"We are proud of Erye's many accomplishments to-date and believe the business is ideally positioned to capture the growth we see ahead," said NeoStem CEO Robin Smith.

New York-based NeoStem, with operations in both the US and China, is set to benefit from the growth of Suzhou Erye, as well as its own stem cell business.

Since starting out as a provider of adult stem cell collection and storage services, NeoStem has since branched out into cell therapeutics, focused on using stem cells to help cure disease.

In January, to enhance its portfolio of services, the company acquired Progenitor Cell Therapy, which has cell therapy manufacturing facilities, as well as processing and storage facilities for stem cells collected from the umbilical cord at birth, on the east and west coast of the US.

As a result of the acquisition, NeoStem can now develop stem cell therapies in-house, placing it in a solid position for future growth in the field.

In addition to its US and Chinese pharma business, NeoStem has also formed two lucrative partnerships with hospitals in China for its stem cell therapies for orthopedic indications.

The company has received a host of recent bullish analyst coverage, including a report issued this morning by equity research firm LifeTech Capital, which gave NeoStem a "strong buy" rating and a price target of $4.00. NeoStem was trading at $1.92 as of 3:00pm EST on Tuesday.

“Proactiveinvestors is a leading news organisation and event business with offices in New York, Sydney, Toronto and London. The Company is a publisher and is not registered with the US Securities Exchange Commission or Ontario Securities Commission. Please read our full terms and conditions herehttp://www.proactiveinvestors.com/pages/terms




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter